Perfusion PET Sarcoma: Feasibility of tumor perfusion quantification with Gallium-68-citrate PET/CT in sarcoma and radiotherapy

Perfusion PET Sarcoma: Feasibility of tumor perfusion quantification with Gallium-68-citrate PET/CT in sarcoma and radiotherapy - Perfusion PET Sarcoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34488

Enrollment

Registered

2010-10-28

Start date

2011-01-01

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma. Soft tissue tumor

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Patients with primary untreated sarcomas referred for preoperative radiotherapy of any site (head and neck, trunk and chest wall, retroperitoneum and extremities); to be divided in a MLS and a non-MLS subgroup. -Willing to undergo additional perfusion PET on the days of the planning CT scan and the days of the 8th, 16th and 25th fraction. -Signed informed consent

Exclusion criteria

Exclusion criteria: -Age

Design outcomes

Primary

Measure	Time frame
(1) Feasibility of the technique. (2) Increased knowledge on vascular response of tumor to radiotherapy, including the difference between MLS and non-MLS.	—

Secondary

Measure	Time frame
(1) Technical optimization of the procedure. (2) new (research) approaches for personalised treatment strategies.	—

Countries

Netherlands

Outcome results